Glass Allison S, Punnen Sanoj, Cooperberg Matthew R
Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Korean J Urol. 2013 Jul;54(7):417-25. doi: 10.4111/kju.2013.54.7.417. Epub 2013 Jul 15.
Today, the majority of men with newly diagnosed prostate cancer will present with low-risk features of the disease. Because prostate cancer often takes an insidious course, it is debated whether the majority of these men require radical treatment and the accompanying derangement of quality of life domains imposed by surgery, radiation, and hormonal therapy. Investigators have identified various selection criteria for "insignificant disease," or that which can be monitored for disease progression while safely delaying radical treatment. In addition to the ideal definition of low risk, a lack of randomized trials comparing the various options for treatment in this group of men poses a great challenge for urologists. Early outcomes from active surveillance cohorts support its use in carefully selected men with low-risk disease features, but frequent monitoring is required. Patient selection and disease monitoring methods will require refinement that will likely be accomplished through the increased use of biomarkers and specialized imaging techniques.
如今,大多数新诊断出前列腺癌的男性患者表现出该疾病的低风险特征。由于前列腺癌通常病程隐匿,对于这些男性中的大多数是否需要进行根治性治疗以及手术、放疗和激素治疗所带来的生活质量方面的相应紊乱,存在争议。研究人员已经确定了“微小疾病”的各种选择标准,即那些可以在安全推迟根治性治疗的同时监测疾病进展的情况。除了低风险的理想定义外,缺乏比较这组男性各种治疗选择的随机试验给泌尿科医生带来了巨大挑战。主动监测队列的早期结果支持在精心挑选的具有低风险疾病特征的男性中使用该方法,但需要频繁监测。患者选择和疾病监测方法需要改进,这可能通过增加生物标志物和专门成像技术的使用来实现。